PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
NYSE:MD - US58502B1061 - Common Stock
17.21 USD
+0.11 (+0.64%)
17.21 USD
0 (0%)
Taking everything into account, MD scores 5 out of 10 in our fundamental rating. MD was compared to 102 industry peers in the Health Care Providers & Services industry. MD has an average financial health and profitability rating. MD is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, MD could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year MD was profitable.
MD had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 5.23%, MD belongs to the best of the industry, outperforming 80.39% of the companies in the same industry.
Looking at the Return On Equity, with a value of 13.18%, MD belongs to the top of the industry, outperforming 81.37% of the companies in the same industry.
MD has a better Return On Invested Capital (9.55%) than 81.37% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MD is in line with the industry average of 9.14%.
The 3 year average ROIC (7.83%) for MD is below the current ROIC(9.55%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROIC | 9.55% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
MD's Profit Margin of 5.66% is amongst the best of the industry. MD outperforms 81.37% of its industry peers.
The Operating Margin of MD (10.97%) is better than 80.39% of its industry peers.
MD's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MD has been increased compared to 1 year ago.
Compared to 5 years ago, MD has more shares outstanding
Compared to 1 year ago, MD has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.00 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.00, MD perfoms like the industry average, outperforming 48.04% of the companies in the same industry.
The Debt to FCF ratio of MD is 2.68, which is a good value as it means it would take MD, 2.68 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MD (2.68) is better than 80.39% of its industry peers.
A Debt/Equity ratio of 0.70 indicates that MD is somewhat dependend on debt financing.
MD has a Debt to Equity ratio (0.70) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Altman-Z | 2 |
ROIC/WACC1.13
WACC8.42%
2.3 Liquidity
A Current Ratio of 1.80 indicates that MD should not have too much problems paying its short term obligations.
MD has a better Current ratio (1.80) than 67.65% of its industry peers.
MD has a Quick Ratio of 1.80. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a Quick ratio of 1.80. This is in the better half of the industry: MD outperforms 68.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.39%, which is quite impressive.
The earnings per share for MD have been decreasing by -15.01% on average. This is quite bad
MD shows a decrease in Revenue. In the last year, the revenue decreased by -3.08%.
The Revenue has been growing slightly by 2.49% on average over the past years.
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
3.2 Future
Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 3.76% on average per year.
MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.34% yearly.
EPS Next Y24.34%
EPS Next 2Y12.88%
EPS Next 3Y10.03%
EPS Next 5Y3.76%
Revenue Next Year-5.69%
Revenue Next 2Y-1.4%
Revenue Next 3Y0.63%
Revenue Next 5Y2.34%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.51 indicates a reasonable valuation of MD.
Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 93.14% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.08, MD is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 9.06, the valuation of MD can be described as reasonable.
MD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 88.24% of the companies in the same industry.
MD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.72.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.51 | ||
| Fwd PE | 9.06 |
4.2 Price Multiples
86.27% of the companies in the same industry are more expensive than MD, based on the Enterprise Value to EBITDA ratio.
94.12% of the companies in the same industry are more expensive than MD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.6 | ||
| EV/EBITDA | 6.9 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y12.88%
EPS Next 3Y10.03%
5. Dividend
5.1 Amount
No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.21
+0.11 (+0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change1.32%
Ins Owners1.88%
Ins Owner Change6.7%
Market Cap1.50B
Analysts78.75
Price Target17.05 (-0.93%)
Short Float %2.15%
Short Ratio2.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.94%
Min EPS beat(2)21.14%
Max EPS beat(2)32.73%
EPS beat(4)4
Avg EPS beat(4)26.19%
Min EPS beat(4)15.9%
Max EPS beat(4)34.96%
EPS beat(8)6
Avg EPS beat(8)10.2%
EPS beat(12)6
Avg EPS beat(12)3.22%
EPS beat(16)9
Avg EPS beat(16)4.71%
Revenue beat(2)0
Avg Revenue beat(2)-1.7%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.44%
Revenue beat(4)1
Avg Revenue beat(4)-0.9%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)1
Avg Revenue beat(12)-2.84%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)-2.5%
PT rev (3m)-7.51%
EPS NQ rev (1m)7.05%
EPS NQ rev (3m)10.98%
EPS NY rev (1m)8.04%
EPS NY rev (3m)10.45%
Revenue NQ rev (1m)0.64%
Revenue NQ rev (3m)0.44%
Revenue NY rev (1m)0.52%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.51 | ||
| Fwd PE | 9.06 | ||
| P/S | 0.77 | ||
| P/FCF | 6.6 | ||
| P/OCF | 6.13 | ||
| P/B | 1.8 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.9 |
EPS(TTM)1.81
EY10.52%
EPS(NY)1.9
Fwd EY11.03%
FCF(TTM)2.61
FCFY15.15%
OCF(TTM)2.81
OCFY16.32%
SpS22.29
BVpS9.57
TBVpS-4.8
PEG (NY)0.39
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROCE | 12.09% | ||
| ROIC | 9.55% | ||
| ROICexc | 11.91% | ||
| ROICexgc | 104.6% | ||
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A | ||
| FCFM | 11.7% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexcg growth 3Y26.95%
ROICexcg growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Debt/EBITDA | 2.47 | ||
| Cap/Depr | 73.88% | ||
| Cap/Sales | 0.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.31% | ||
| Profit Quality | 206.51% | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 2 |
F-Score7
WACC8.42%
ROIC/WACC1.13
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
EPS Next Y24.34%
EPS Next 2Y12.88%
EPS Next 3Y10.03%
EPS Next 5Y3.76%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
Revenue Next Year-5.69%
Revenue Next 2Y-1.4%
Revenue Next 3Y0.63%
Revenue Next 5Y2.34%
EBIT growth 1Y39.69%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year41.46%
EBIT Next 3Y15.15%
EBIT Next 5YN/A
FCF growth 1Y63.28%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y43.72%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%